Table 1.
Clinical characteristics of patients with triple-negative breast cancer.
Fig 1.
Myxoid change as an independent predictor of survival in patients with triple-negative breast cancer.
(a) (b) Representative image of myxoid change in triple-negative breast cancer. Accumulation of amorphous stromal substances around the tumor nests (arrows) (x 100 (a) and x 200 (b)). (c) Only fibrous stroma is present, and no myxoid change is observed around the tumor nests (x 200). (d) Kaplan–Meier curves for the overall survival (OS) and relapse-free survival (RFS) of patients with triple-negative breast cancer. OS (left) and RFS (right) curves among myxoid change-positive (red line) and myxoid change-negative (blue line) patients.
Table 2.
Association of myxoid change with clinicopathological factors.
Fig 2.
Fibrotic focus as an independent predictor of survival in patients with triple-negative breast cancer.
(a) (b) Representative image of fibrotic focus (FF) in triple-negative breast cancer. Fibrotic area within the tumor containing collagen surrounded by a highly cellular zone of infiltrating carcinoma (arrows) (x 40 (a) and x 100 (b)). (c) No FF is observed within the tumor (x 40). (d) Kaplan-Meier curves for the overall survival (OS) and relapse-free survival (RFS) of triple-negative patients with breast cancer. OS (left) and RFS (right) curves among FF-positive (red line) and FF-negative (blue line) patients.
Table 3.
Association of fibrotic focus with clinicopathological factors.
Fig 3.
Survival for myxoid change- and fibrotic focus-positive patients vs. myxoid change- and/or fibrotic focus-negative patients.
Overall survival (OS) (left) and relapse-free survival (RFS) (right) curves in myxoid change and FF-positive (red line) and myxoid change- and/or FF-negative (blue line) patients.
Table 4.
Association of myxoid change and fibrotic focus with clinicopathological factors.
Table 5.
Multivariate analysis of relapse-free survival.
Fig 4.
Survival analyses for myxoid change, fibrotic focus (FF), and a combination of myxoid change and FF in patients with adjuvant chemotherapy.
(a) Kaplan–Meier curves for the overall survival (OS) and relapse-free survival (RFS) of patients with adjuvant chemotherapy. OS (left) and RFS (right) curves among myxoid change-positive (red line) and myxoid change-negative (blue line) patients. (b) OS (left) and RFS (right) curves among FF-positive (red line) and FF-negative (blue line) patients. (c) Overall survival (OS) (left) and relapse-free survival (RFS) (right) curves in myxoid change and FF-positive (red line) and myxoid change- and/or FF-negative (blue line) patients.
Fig 5.
Survival analyses for myxoid change, fibrotic focus (FF), and a combination of myxoid change and fibrotic focus in patients without adjuvant chemotherapy.
(a) Kaplan–Meier curves for the overall survival (OS) and relapse-free survival (RFS) of patients without adjuvant chemotherapy. OS (left) and RFS (right) curves among myxoid change-positive (red line) and myxoid change-negative (blue line) patients. (b) OS (left) and RFS (right) curves among FF-positive (red line) and FF-negative (blue line) patients. (c) Overall survival (OS) (left) and relapse-free survival (RFS) (right) curves in myxoid change and FF-positive (red line) and myxoid change- and/or FF-negative (blue line) patients.